| # | Drug | Count |
|---|---|---|
| 0 | ADALIMUMAB | 31 |
| 1 | LENALIDOMIDE | 20 |
| 2 | FINGOLIMOD HCL | 17 |
| 3 | ADALIMUMAB-AATY | 14 |
| 4 | ADALIMUMAB-ADAZ | 14 |
| 5 | PREDNISONE | 14 |
| 6 | ADALIMUMAB-FKJP | 13 |
| 7 | METHOTREXATE SODIUM | 13 |
| 8 | INFLIXIMAB | 11 |
| 9 | METHOTREXATE | 11 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | CHENODIOL | 1 | 0.0028 |
| 1 | TINIDAZOLE | 1 | 0.0023 |
| 2 | OMAVELOXOLONE | 2 | 0.0011 |
| 3 | RESMETIROM | 2 | 0.0009 |
| 4 | ELIGLUSTAT | 1 | 0.0006 |
| 5 | SELUMETINIB | 1 | 0.0006 |
| 6 | TALAZOPARIB | 1 | 0.0005 |
| 7 | ROPEGINTERFERON ALFA-2B | 1 | 0.0005 |
| 8 | ISOFLURANE | 1 | 0.0005 |
| 9 | IVOSIDENIB | 1 | 0.0005 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 33 |
| 1 | Kinase Inhibitor [EPC] | 21 |
| 2 | Thalidomide Analog [EPC] | 21 |
| 3 | Nonsteroidal Anti-inflammatory Drug [EPC] | 19 |
| 4 | Tumor Necrosis Factor Blocker [EPC] | 15 |
| 5 | Folate Analog Metabolic Inhibitor [EPC] | 11 |
| 6 | Platelet Aggregation Inhibitor [EPC] | 10 |
| 7 | Proton Pump Inhibitor [EPC] | 10 |
| 8 | Purine Antimetabolite [EPC] | 10 |
| 9 | Angiotensin 2 Receptor Blocker [EPC] | 9 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Thyroid Hormone Receptor beta Agonist [EPC] | 2 | 0.0009 |
| 1 | Interferon alfa-2b [EPC] | 1 | 0.0005 |
| 2 | Isocitrate Dehydrogenase 1 Inhibitor [EPC] | 1 | 0.0005 |
| 3 | Glucosylceramide Synthase Inhibitor [EPC] | 1 | 0.0004 |
| 4 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 1 | 0.0002 |
| 5 | Blood Viscosity Reducer [EPC] | 1 | 0.0002 |
| 6 | GLP-2 Analog [EPC] | 3 | 0.0002 |
| 7 | Progestin Antagonist [EPC] | 1 | 0.0002 |
| 8 | SLAMF7-directed Immunostimulatory Antibody [EPC] | 1 | 0.0002 |
| 9 | Bile Acid [EPC] | 4 | 0.0002 |